KY02111 is primarily used in research settings as a potent and selective inhibitor of the Wnt/β-catenin signaling pathway. This pathway plays a critical role in cell proliferation, differentiation, and stem cell maintenance, and its dysregulation is associated with various cancers and developmental disorders. KY02111 effectively disrupts the interaction between β-catenin and its transcriptional co-activators, thereby suppressing the expression of Wnt target genes. Due to its specific mechanism, KY02111 is widely applied in oncology research, particularly in studies focused on colorectal, liver, and breast cancers where Wnt signaling is often hyperactive. It serves as a valuable tool compound for validating the therapeutic potential of targeting the Wnt pathway. Additionally, KY02111 is used in stem cell and regenerative medicine research to modulate cell fate decisions by fine-tuning Wnt activity. Its application extends to in vitro and in vivo models where controlled inhibition of Wnt signaling helps elucidate pathway dynamics and supports the development of novel anti-cancer strategies. KY02111 is not used clinically but remains an important molecule in preclinical drug discovery and pathway analysis.